September 2025
M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Science

George Touma Highlights DCB-BIF Trial: Drug-Coated Balloons Improve Outcomes in Coronary Bifurcation PCI

George Touma/LinkedIn

Sep 12, 2025, 09:03

George Touma Highlights DCB-BIF Trial: Drug-Coated Balloons Improve Outcomes in Coronary Bifurcation PCI

George Touma, Interventional Cardiologist at St George Private Cardiology, posted on LinkedIn:

” What is the DCB-BIF Trial?

The DCB-BIF (Drug-Coated Balloon in Bifurcations) trial is the first well powered, multicenter randomized study comparing drug-coated balloon (DCB) angioplasty versus conventional non-compliant balloon (NCB) angioplasty for the side branch (SB) in patients with true but “simple” coronary bifurcation lesions treated using a provisional stenting strategy.

Conducted across 22 centers in China, Indonesia, Italy, and Korea, it enrolled 784 patients.

Study Design and Patients
• Included patients with true bifurcations (Medina 1,1,1; 0,1,1; or 1,0,1) and SB ostial stenosis ≥70% after main vessel (MV) stenting and proximal optimization (POT).
• Randomized 1:1 into two groups:
– DCB arm – SB treated with a paclitaxel-coated balloon
– NCB arm – SB treated with a standard non-compliant balloon
• Primary endpoint: 1-year MACE (cardiac death, target-vessel MI, clinically driven TLR).
• Patients: median age 65 years, 23% women.

Key Findings
MACE at 1 year:
• 7.2% in the DCB group
• 12.5% in the NCB group
Benefit driven by lower target-vessel MI.
Rates of cardiac death, TLR, procedural success, two-stent crossover, all-cause death, and stent thrombosis were similar.

Interpretation and Significance
• DCB for SB angioplasty improves outcomes compared to conventional ballooning in this scenario.
• As the first large RCT powered for clinical outcomes, DCB-BIF provides evidence for incorporating DCBs into bifurcation PCI strategies.

Broader Context and Research
• Before DCB-BIF: evidence was limited to small RCTs and meta-analyses focused on angiographic outcomes like late lumen loss (LLL). These suggested better SB patency and possible MI reduction, but lacked power.
• Meta-analysis of 5 RCTs (~1,255 patients): DCBs reduced MI risk (RR = 0.56; p=0.01), though no significant differences in overall MACE, TLR, or mortality.

The Five RCTs used in this meta analysis:
1. Herrador et al., 2013 (Spain) – Non-randomized (NRCT) study using SeQuent Please paclitaxel-eluting balloon.
2. Zong et al., 2018 (China) – RCT, SeQuent Please paclitaxel-eluting balloon.
3. Zhang et al., 2019 (China) – NRCT, SeQuent Please paclitaxel-eluting balloon.
4. Jing et al., 2020 (China) – RCT, Bingo paclitaxel-eluting balloon.
5. Bu et al., 2021 (China) – RCT, DCB (unspecified brand).

• PEPCAD-BIF trial (~64 patients): showed less late lumen loss with DCB vs plain balloons.

• Ongoing trials (e.g., OCVC-BIF) are testing additional DCB use after kissing balloon inflation versus standard approaches, aiming to refine bifurcation PCI strategies.

Take-Home Message
The DCB-BIF trial establishes DCB angioplasty as a clinically superior side-branch strategy in provisional bifurcation PCI – delivering fewer MIs. Its my default strategy.”

Stay updated with Hemostasis Today.

Cardiology Coronary Bifurcation PCI DCB angioplasty DCB-BIF Trial Drug Coated Balloons George Touma Health Hematology Hemostasis Hemostasis Today Medicine MI Myocardial infarction St George Private Cardiology thrombosis

Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation

The Role of Pharmacogenetics in Personalising Stroke Care: World Stroke Academy Webinar Chaired by Prof. Simona Sacco

Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial

Do Not Miss ISTH Fast Five! Pediatric and Neonatal Thrombosis & Hemostasis and Many More Webinars

WFH Global Forum Returns to Montreal - Register Now!